Scriptaid
Based on 4 publication(s) in Google Scholar
Scriptaid is a potent histone deacetylase (HDAC) inhibitor, used in cancer research. Scriptaid is also a sensitizer to antivirals and has potential for epstein-barr virus (EBV)-associated lymphomas treatment.
For research use only. We do not sell to patients.
- Purity: 98.09%
- CAS No.: 287383-59-9
- Formula: C18H18N2O4
- Molecular Weight:326.35
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Scriptaid
More
Customer Validation & Images
-
WB
Biological Activity
|
HDAC |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Huh-7 | CC50 |
3.32 μM
Compound: GNF-Pf-2024
|
NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)
NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)
|
[PMID: 18579783] |
| Jurkat | IC50 |
6.1 μM
Compound: 28
|
Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 24 hrs by Celltiter-Glo assay
Cytotoxicity against human Jurkat cells assessed as reduction in cell viability measured after 24 hrs by Celltiter-Glo assay
|
[PMID: 37429084] |
| Kasumi 1 | IC50 |
0.49 μM
Compound: Scriptaid
|
Antiproliferative activity against human Kasumi-1 cells after 72 hrs by resazurin dye-based assay
Antiproliferative activity against human Kasumi-1 cells after 72 hrs by resazurin dye-based assay
|
[PMID: 30448419] |
| Sf21 | IC50 |
1.74 μM
Compound: Scriptaid
|
Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 (1 to 482 residues) expressed in sf21 cells using RHK-K(Ac)-AMC as substrate by fluorimetric assay
Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 (1 to 482 residues) expressed in sf21 cells using RHK-K(Ac)-AMC as substrate by fluorimetric assay
|
[PMID: 30448419] |
Scriptaid (1 μg/mL) treatment inhibits cell growth in breast cancer cell lines, results in increased accumulation of both acetyl H3 and acetyl H4 proteins in MDA-MB-231, MDA-MB-435, and Hs578t cells. Scriptaid also inhibits cell growth of MDA-MB-231, MDA-MB-435, and Hs578t cell lines, with IC50s of 0.5-1.0 μg/mL. Scriptaid (0.1-1.0 μg/mL) induces ER and PR mRNA expression in a dose dependent manner; when it is combined with AZA, they enhance ER expression and induce a functional ER protein[1]. Scriptaid and SAHA preferentially inhibit the Class I histone deacetylases, hdac1, 2, and 3. Scriptaid is a potent anti-T. gondii compound with low cytotoxicity, and the IC50 is 39 nM. Scriptaid has atypical effects in T. gondiiinfected HS68 cells[2]. Scriptaid inhibits the growth of HeLa cells with IC50 of 2 μM at 48 h in a dose-dependent manner. Scriptaid also affects cell-cycle and apoptosis[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 287383-59-9
-
Appearance Solid
-
Molecular Weight 326.35
-
Formula C18H18N2O4
-
Color White to off-white
-
SMILES
O=C(NO)CCCCCN(C(C1=CC=CC2=CC=CC3=C12)=O)C3=O
-
Synonyms
Scriptide; GCK1026
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (4)
-
Journal Impact Factor
-
Most Recent
-
Proc Natl Acad Sci U S A
2019 Feb 19;116(8):2961-2966. PMID: 30718431 -
Cancer Cell Int
Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer. [Abstract]2021 Jun 5;21(1):291. PMID: 34090418 -
J Cell Mol Med
Low levels of AMPK promote epithelial-mesenchymal transition in lung cancer primarily through HDAC4- and HDAC5-mediated metabolic reprogramming. [Abstract]2020 Jul;24(14):7789-7801. PMID: 32519437
Scriptaid purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2020 Jul;24(14):7789-7801. [Abstract]
Western blot analysis show that Scriptaid partially counteracts siAMPK‐LV‐induced increase in HK2 expression at both protein and gene and had no effect on the expression of AMPK.
-
bioRxiv
2025 Jul 12:2025.07.08.663754. PMID: 40672312
Solvent & Solubility
DMSO : 100 mg/mL (306.42 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.66 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.66 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
IC50 concentrations of Scriptaid are determined in MDA-MB-231, MDA-MB-435 and Hs578t cells by MTT assay. For cell growth assays, MDA-MB-231, MDA-MB-435, and Hs578t cells are plated at a cell density of 5000 cells/well in 12 well plates and treated with 1.0 µg/mL Scriptaid for up to 3 days. Cells are counted daily using a Coulter counter. Percent growth inhibition is determined by comparison of treated and untreated cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Four to six week old athymic female nude mice are housed under laminar flow hoods in an environmentally controlled pathogen free animal facility for the duration of experiments. Mice are injected with 2×106 MDA-MB-231 human breast cancer cells into each flank. Tumors are allowed to grow to approximately 0.1 cm3 in diameter before treatment. Mice are then treated with Scriptaid (3.5 µg/g mouse), TSA (0.5 µg/g mouse), or DMSO vehicle intraperitoneally for five consecutive days with 2 days rest each week for a total of 4 weeks. Individual tumor measurements are recorded from each flank weekly[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Keen JC, et al. A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res Treat. 2003 Oct;81(3):177-86. [Content Brief]
[2]. Strobl JS, et al. Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro. J Parasitol. 2007 Jun;93(3):694-700. [Content Brief]
[3]. Janaki Ramaiah M, et al. Scriptaid cause histone deacetylase inhibition and cell cycle arrest in HeLa cancer cells: A study on structural and functional aspects. Gene. 2017 Sep 5;627:379-386. [Content Brief]
[4]. Ghosh SK, et al. Histone deacetylase inhibitors are potent inducers of gene expression in latent EBV and sensitize lymphoma cells to nucleoside antiviral agents. Blood. 2012 Jan 26;119(4):1008-17. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.0642 mL | 15.3210 mL | 30.6419 mL | 76.6049 mL |
| 5 mM | 0.6128 mL | 3.0642 mL | 6.1284 mL | 15.3210 mL | |
| 10 mM | 0.3064 mL | 1.5321 mL | 3.0642 mL | 7.6605 mL | |
| 15 mM | 0.2043 mL | 1.0214 mL | 2.0428 mL | 5.1070 mL | |
| 20 mM | 0.1532 mL | 0.7660 mL | 1.5321 mL | 3.8302 mL | |
| 25 mM | 0.1226 mL | 0.6128 mL | 1.2257 mL | 3.0642 mL | |
| 30 mM | 0.1021 mL | 0.5107 mL | 1.0214 mL | 2.5535 mL | |
| 40 mM | 0.0766 mL | 0.3830 mL | 0.7660 mL | 1.9151 mL | |
| 50 mM | 0.0613 mL | 0.3064 mL | 0.6128 mL | 1.5321 mL | |
| 60 mM | 0.0511 mL | 0.2553 mL | 0.5107 mL | 1.2767 mL | |
| 80 mM | 0.0383 mL | 0.1915 mL | 0.3830 mL | 0.9576 mL | |
| 100 mM | 0.0306 mL | 0.1532 mL | 0.3064 mL | 0.7660 mL |
Scriptaid Related Classifications
HY-15489 Related Classifications
Powered by Bioz